Search Results

Press Releases

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

December 6, 2024

·

6 min read

Job Trends

Medici Facilitates Telemedicine Teamwork with New Feature Enabling Group Consultations

On the heels of Chat Translate, Medici introduces Chat Collaboration to enable providers to add colleagues to telemedicine consults with patients on the Medici platform

September 5, 2019

·

2 min read

Press Releases

MediciNova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders

November 20, 2024

·

8 min read

Job Trends

Medici Receives SOC 2 Type II Attestation

Medici, a virtual healthcare company based in Austin, Texas announced that it has completed its SOC 2 Type II audit.

February 4, 2020

·

2 min read

Press Releases

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

November 15, 2024

·

6 min read

Press Releases

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

October 24, 2024

·

5 min read

Press Releases

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

September 30, 2024

·

6 min read

Job Trends

Medici Wins Silver in 9th Annual Best in Biz Awards

Medici has been named a silver winner in the Most Innovative Product of the Year--Healthcare category in Best in Biz Awards, the only independent business awards program judged by prominent editors and reporters from top-tier publications in North America.

December 19, 2019

·

4 min read

Drug Development

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

September 9, 2024

·

4 min read

Drug Development

MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting

September 3, 2024

·

4 min read